CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia
Joshua Gustine(Harvard University), Jorge J. Castillo(Miriam Hospital), Christopher J. Patterson(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Maria Luisa Guerrera(Harvard University), Andrew Keezer(Dana-Farber Cancer Institute), Manit Munshi(Dana-Farber Cancer Institute), Kirsten Meid(Shaanxi Research Association for Women and Family), Steven P. Treon(Harvard University), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Harvard University), Xia Liu(Guangxi University), Lian Xu(Huazhong Agricultural University), Zachary R. Hunter(Shaanxi Research Association for Women and Family)
Cited by 39
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
|Journal of Clinical Oncology|2018|176
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
|Journal of Clinical Oncology|2020|165